Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 339-344 , September 2009

Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma

Received 20 April 2009 ,Revised 15 June 2009 ,Accepted 24 June 2009.

References 

  1. Heimberger AB, Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Patients CNS Drug Discov. 2008;3:179–188
  2. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Invest Drugs. 2009;18:45–56
  3. Willey CD, Palanisamy AP, Johnston RK, et al. STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. Int J Biol Sci. 2008;4:184–199
  4. Haura EB, Zheng Z, Song L, et al. Activated epidermal growth factor receptor – STAT-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005;11:8288–8294
  5. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of STAT-3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci (PNAS). 2000;97:4227–4232
  6. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of STAT-3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–115
  7. Boehm AL, Sen M, Seethala R, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-XL enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol. 2008;73:1632–1642
  8. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272
  9. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT-3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101:1535–1542
  10. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18:47s–53s
  11. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006;12:1398–1401
  12. Bonner JA, Maihle NJ, Folven BR, et al. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiation Oncology Biol Phys. 1994;29:243–247
  13. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935–1940
  14. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14:451–463
  15. Dobelbower MC, Russo SM, Raisch KP, et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotnib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anti-Cancer Drugs. 2006;17:95–102
  16. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  17. Fertil B, Dertinger H, Courdi A, et al. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res. 1984;99:73–84
  18. Colton T. In: Statistics in medicine. Boston, MA: Little, Brown; 1974;p. 131–136
  19. Bonner JA, Buchsbaum DJ, Russo SM, et al. Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. Int J Radiat Oncol Biol Phys. 2004;59:2–10
  20. Zhang Z, Wang H, Li M, et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem. 2004;279:16000–16006
  21. Hawthorne VS, Huang WC, Neal CL, et al. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res. 2009;7:592–600
  22. Onishi A, Chen Q, Humtsoe JO, et al. STAT3 signaling is induced by intercellular adhesion in squamous cell carcinoma cells. Exp Cell Res. 2008;314:377–386
  23. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block STAT3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276:45443–45455
  24. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004;3:261–269
  25. Turkson J, Zhang S, Mora LB, et al. A novel platinum compound inhibits constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem. 2005;280:32979–32988
  26. Timofeeva OA, Gaponenko V, Lockett SJ, et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol. 2007;2:799–809

☆ Presented at the 11th International Wolfsberg Meeting, 2009.

PII: S0167-8140(09)00333-8

doi: 10.1016/j.radonc.2009.06.022

Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 339-344 , September 2009

Article Tools

* Image Usage & Resolution